<DOC>
	<DOCNO>NCT00795171</DOCNO>
	<brief_summary>Docetaxel sunitinib compare docetaxel effect CEC/CEP spike induce docetaxel HRPC patient</brief_summary>
	<brief_title>Biomarker Study Sunitinib Docetaxel Prostate Cancer</brief_title>
	<detailed_description>Docetaxel ( 75mg/m2 q21d ) standard care patient hormone refractory prostate cancer ( HRPC ) . Recent data indicate , chemotherapeutics give MTD induce , besides cytotoxic effect , mobilization circulate endothelial cell ( CEC ) - progenitor ( CEP ) drug-free breaks cycle . In preclinical model , mobilize CEC/CEP result tumor vasculogenesis progression disease . We hypothesize treatment sunitinib , anti-angiogenic tyrosine kinase inhibitor , 3 weekly docetaxel disrupts CEC/CEP spike follow docetaxel lead chemosensitization reduce tumor re-growth HRPC patient respond docetaxel .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>WHO performance status 02 . Histologically proven prostate adenocarcinoma . All patient must prostate adenocarcinoma unresponsive refractory androgen ablation biochemical progression Measurable and/or evaluable progressive disease , define one follow three criterion : 25 % increase bidimensionally measurable soft tissue metastasis Appearance new metastatic lesion ( proven CT scan , Xray bone scan ) PSA level least 10ng/mL , increase least 2 successive occasion least 2 week apart If patient treat antiandrogens , treatment must stop least 6 week prior study randomization prior chemotherapy prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>